 John DeSisto
Concepts (139)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glioma | 10 | 2025 | 426 | 3.000 |
Why?
| | Brain Neoplasms | 9 | 2025 | 1322 | 1.600 |
Why?
| | Protein-Arginine N-Methyltransferases | 1 | 2025 | 25 | 0.870 |
Why?
| | Radiation | 1 | 2021 | 24 | 0.690 |
Why?
| | Neoplastic Stem Cells | 1 | 2025 | 412 | 0.660 |
Why?
| | Receptors, Nerve Growth Factor | 1 | 2019 | 18 | 0.610 |
Why?
| | Meninges | 1 | 2020 | 49 | 0.610 |
Why?
| | Karyopherins | 1 | 2019 | 20 | 0.610 |
Why?
| | NF-kappa B | 2 | 2019 | 662 | 0.560 |
Why?
| | Transcriptome | 3 | 2025 | 1046 | 0.540 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 2019 | 210 | 0.540 |
Why?
| | Cerebellar Neoplasms | 3 | 2025 | 177 | 0.500 |
Why?
| | Medulloblastoma | 3 | 2025 | 215 | 0.490 |
Why?
| | Fibroblasts | 1 | 2020 | 1034 | 0.430 |
Why?
| | Microbubbles | 2 | 2024 | 53 | 0.420 |
Why?
| | Gene Expression Regulation, Neoplastic | 7 | 2025 | 1462 | 0.400 |
Why?
| | Blood-Brain Barrier | 2 | 2024 | 155 | 0.390 |
Why?
| | Rhabdoid Tumor | 2 | 2025 | 103 | 0.380 |
Why?
| | DNA Copy Number Variations | 2 | 2023 | 183 | 0.350 |
Why?
| | Hydrazines | 2 | 2025 | 37 | 0.340 |
Why?
| | Epigenesis, Genetic | 3 | 2025 | 685 | 0.320 |
Why?
| | Triazoles | 2 | 2025 | 184 | 0.300 |
Why?
| | Neoplasm Grading | 2 | 2021 | 309 | 0.300 |
Why?
| | Cell Line, Tumor | 8 | 2025 | 3550 | 0.300 |
Why?
| | Brain | 2 | 2024 | 2941 | 0.290 |
Why?
| | Ependymoma | 2 | 2023 | 176 | 0.280 |
Why?
| | SMARCB1 Protein | 2 | 2025 | 34 | 0.270 |
Why?
| | Gene Expression Profiling | 2 | 2024 | 1786 | 0.240 |
Why?
| | Astrocytoma | 2 | 2025 | 129 | 0.240 |
Why?
| | Disease Progression | 2 | 2024 | 2852 | 0.240 |
Why?
| | 12E7 Antigen | 1 | 2025 | 10 | 0.230 |
Why?
| | Mice | 9 | 2025 | 18365 | 0.220 |
Why?
| | Child | 9 | 2025 | 22657 | 0.220 |
Why?
| | Ganglioglioma | 1 | 2025 | 34 | 0.220 |
Why?
| | Sirtuin 2 | 1 | 2025 | 27 | 0.220 |
Why?
| | Sonication | 1 | 2024 | 12 | 0.220 |
Why?
| | Drug Screening Assays, Antitumor | 2 | 2021 | 191 | 0.200 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2025 | 226 | 0.190 |
Why?
| | Single-Cell Analysis | 3 | 2025 | 359 | 0.190 |
Why?
| | Carcinogenesis | 1 | 2025 | 229 | 0.190 |
Why?
| | Central Nervous System Neoplasms | 1 | 2025 | 174 | 0.190 |
Why?
| | Antineoplastic Agents | 3 | 2020 | 2197 | 0.180 |
Why?
| | Teratoma | 1 | 2023 | 120 | 0.180 |
Why?
| | Microglia | 1 | 2024 | 269 | 0.180 |
Why?
| | raf Kinases | 1 | 2021 | 11 | 0.180 |
Why?
| | Gene Ontology | 1 | 2021 | 54 | 0.170 |
Why?
| | Animals | 10 | 2025 | 38109 | 0.170 |
Why?
| | Tumor Microenvironment | 1 | 2025 | 735 | 0.160 |
Why?
| | Genes, myc | 1 | 2020 | 51 | 0.160 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2025 | 883 | 0.160 |
Why?
| | Humans | 19 | 2025 | 144957 | 0.160 |
Why?
| | Protein-Tyrosine Kinases | 2 | 2020 | 433 | 0.150 |
Why?
| | Recurrence | 1 | 2023 | 1135 | 0.150 |
Why?
| | DNA Methylation | 2 | 2023 | 683 | 0.150 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2021 | 211 | 0.150 |
Why?
| | Crystallins | 1 | 2020 | 61 | 0.150 |
Why?
| | MAP Kinase Signaling System | 1 | 2021 | 311 | 0.150 |
Why?
| | Mutation | 3 | 2025 | 4099 | 0.150 |
Why?
| | Cell Proliferation | 2 | 2025 | 2499 | 0.150 |
Why?
| | Pyrimidinones | 1 | 2020 | 126 | 0.150 |
Why?
| | Histones | 1 | 2024 | 670 | 0.140 |
Why?
| | Deoxycytidine | 1 | 2020 | 221 | 0.140 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2025 | 1141 | 0.140 |
Why?
| | Antibodies, Monoclonal | 1 | 2025 | 1524 | 0.130 |
Why?
| | Phenotype | 2 | 2024 | 3164 | 0.130 |
Why?
| | Everolimus | 1 | 2017 | 111 | 0.130 |
Why?
| | Transfection | 1 | 2019 | 940 | 0.130 |
Why?
| | Morpholines | 1 | 2017 | 129 | 0.130 |
Why?
| | Nuclear Proteins | 2 | 2023 | 749 | 0.130 |
Why?
| | Brain Stem Neoplasms | 1 | 2017 | 87 | 0.130 |
Why?
| | Computer Simulation | 1 | 2021 | 1026 | 0.120 |
Why?
| | Macrophages | 1 | 2024 | 1511 | 0.120 |
Why?
| | Mice, Inbred C57BL | 3 | 2024 | 5997 | 0.120 |
Why?
| | Immunophenotyping | 1 | 2017 | 322 | 0.120 |
Why?
| | Glioblastoma | 1 | 2019 | 353 | 0.120 |
Why?
| | Cell Cycle | 2 | 2017 | 597 | 0.120 |
Why?
| | Inflammation | 2 | 2024 | 2880 | 0.120 |
Why?
| | Pyrazoles | 1 | 2020 | 510 | 0.120 |
Why?
| | Cell Cycle Proteins | 1 | 2020 | 629 | 0.120 |
Why?
| | Cell Tracking | 1 | 2015 | 19 | 0.120 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2017 | 437 | 0.110 |
Why?
| | Tumor Suppressor Proteins | 1 | 2017 | 321 | 0.110 |
Why?
| | Genetic Variation | 1 | 2019 | 984 | 0.110 |
Why?
| | Cohort Studies | 2 | 2023 | 5965 | 0.110 |
Why?
| | Biomarkers, Tumor | 1 | 2019 | 1322 | 0.090 |
Why?
| | Female | 9 | 2025 | 78376 | 0.090 |
Why?
| | Adolescent | 4 | 2025 | 22453 | 0.080 |
Why?
| | Neoplasms | 1 | 2025 | 2884 | 0.070 |
Why?
| | Young Adult | 2 | 2025 | 14126 | 0.070 |
Why?
| | Isocitrate Dehydrogenase | 1 | 2025 | 70 | 0.060 |
Why?
| | Child, Preschool | 3 | 2025 | 11799 | 0.060 |
Why?
| | Radiation Tolerance | 1 | 2025 | 103 | 0.060 |
Why?
| | Receptors, CCR1 | 1 | 2024 | 4 | 0.050 |
Why?
| | Ultrasonic Waves | 1 | 2024 | 10 | 0.050 |
Why?
| | Maximum Tolerated Dose | 1 | 2025 | 212 | 0.050 |
Why?
| | Receptors, CCR5 | 1 | 2024 | 60 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2025 | 167 | 0.050 |
Why?
| | Male | 7 | 2025 | 72406 | 0.050 |
Why?
| | Cell Differentiation | 2 | 2025 | 2050 | 0.050 |
Why?
| | Histology | 1 | 2023 | 4 | 0.050 |
Why?
| | Chromosomes, Human, Pair 10 | 1 | 2023 | 19 | 0.050 |
Why?
| | Myeloid Cells | 1 | 2024 | 148 | 0.050 |
Why?
| | Cell Survival | 2 | 2017 | 1098 | 0.050 |
Why?
| | Chromosomes, Human, Pair 1 | 1 | 2023 | 79 | 0.050 |
Why?
| | Particle Size | 1 | 2024 | 411 | 0.050 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2025 | 930 | 0.050 |
Why?
| | Mitosis | 1 | 2023 | 200 | 0.040 |
Why?
| | DNA Helicases | 1 | 2023 | 143 | 0.040 |
Why?
| | Magnetic Resonance Imaging | 2 | 2024 | 3869 | 0.040 |
Why?
| | Cerebellum | 1 | 2023 | 223 | 0.040 |
Why?
| | Contrast Media | 1 | 2024 | 488 | 0.040 |
Why?
| | Chromatin | 1 | 2025 | 561 | 0.040 |
Why?
| | Sequence Analysis, RNA | 1 | 2023 | 442 | 0.040 |
Why?
| | Drug Delivery Systems | 1 | 2024 | 381 | 0.040 |
Why?
| | Dendritic Cells | 1 | 2023 | 499 | 0.040 |
Why?
| | Mechanistic Target of Rapamycin Complex 2 | 1 | 2017 | 63 | 0.030 |
Why?
| | Infant | 2 | 2023 | 10039 | 0.030 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 1 | 2017 | 139 | 0.030 |
Why?
| | Apoptosis | 1 | 2025 | 2430 | 0.030 |
Why?
| | Benzamides | 1 | 2017 | 224 | 0.030 |
Why?
| | Enzyme Inhibitors | 1 | 2020 | 826 | 0.030 |
Why?
| | Proto-Oncogene Proteins | 1 | 2019 | 623 | 0.030 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2019 | 550 | 0.030 |
Why?
| | Transcriptional Activation | 1 | 2017 | 383 | 0.030 |
Why?
| | Active Transport, Cell Nucleus | 1 | 2015 | 121 | 0.030 |
Why?
| | Cell Cycle Checkpoints | 1 | 2015 | 99 | 0.030 |
Why?
| | Transcription Factors | 1 | 2023 | 1742 | 0.030 |
Why?
| | Cell Culture Techniques | 1 | 2017 | 375 | 0.030 |
Why?
| | Mice, Transgenic | 1 | 2020 | 2185 | 0.030 |
Why?
| | Pyrimidines | 1 | 2017 | 533 | 0.030 |
Why?
| | Cell Death | 1 | 2015 | 383 | 0.030 |
Why?
| | Disease Models, Animal | 1 | 2024 | 4569 | 0.030 |
Why?
| | Fluorescent Dyes | 1 | 2015 | 330 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2017 | 2032 | 0.020 |
Why?
| | Phosphorylation | 1 | 2017 | 1733 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2017 | 1258 | 0.020 |
Why?
| | Prognosis | 1 | 2019 | 4293 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2025 | 11695 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2019 | 6434 | 0.020 |
Why?
|
|
DeSisto's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|